COMPLEX THERAPY OF ADENOMYOSIS IN WOMEN OF REPRODUCTIVE AGE

K.I. Susak, В.В. Курочка
In: Medical Science of Ukraine (MSU) · 2025 · vol. 21(4) , pp. 13–22 · doi:10.32345/2664-4738.4.2025.02 · W7140220453
article OA: diamond CC0
🔓 Open OA copy Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-06 ⓘ

This study compared complex adenomyosis therapy to dienogest, finding the complex therapy improved quality of life and normalized tumor markers, immune status, and hematological parameters more effectively.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-06 · read from full text ⓘ

This paper studied effects of complex therapy for adenomyosis in 90 women of reproductive age, comparing a combination regimen (including a GnRH agonist plus an immunomodulator and local hyaluronic acid and rectal suppositories with streptokinase/streptodornase) versus dienogest alone for 6 months, with assessments at 3, 6, and 12 months; 30 healthy women served as controls. The authors report that complex therapy produced a larger improvement in clinical and biomarker outcomes than dienogest, including a 3.7-fold decrease in CA-125, increases in hemoglobin, ferritin, and serum iron, and changes in immune/hormonal parameters (including NK cytotoxic index increases and FSH/LH and estradiol decreases), alongside better physical and psychological quality-of-life components. A stated limitation is the comparator regimen and outcomes are limited to the parameters measured over the 12-month follow-up period, without broader long-term safety or efficacy outcomes described in the abstract. This paper is centrally about adenomyosis — it evaluates complex combination therapy’s effects on immunological status, hormonal homeostasis, and quality of life compared with dienogest.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Background: Adenomyosis is accompanied by impaired menstrual function, reproductive health, pain syndrome, anemia, and reduces the quality of life of women. Aim: to assess the impact of complex therapy for adenomyosis on immunological status, hormonal homeostasis, and quality of life in women of reproductive age. Materials and methods. The effect of hormone therapy was evaluated in 90 women with adenomyosis (main group), who were divided into two comparable groups depending on the treatment received. Women in group I (n=45) used complex therapy: gonadotropin-releasing hormone agonist, immunomodulator, vaginal suppositories with hyaluronic acid, rectal suppositories with streptokinase and streptodornase; group II (n=45) received dienogest once a day for 6 months. Health indicators were assessed 3, 6 and 12 months. Control group of 30 healthy women of reproductive age. Results. The effects of combination therapy and dienogest on the clinical course, menstrual blood loss volume, and indicators of immune and humoral homeostasis in women with adenomyosis were studied. The treatment led to a 3.7-fold decrease in the tumor marker CA 125, a 1.3-fold increase in hemoglobin levels, a 4.4-fold increase in ferritin, a 2.5-fold increase in serum iron, a 1.7-fold increase in the cytotoxic index of NK cells, a 2-fold decrease in FSH, a 1.5-fold decrease in LH, and a 1.9-fold decrease in estradiol during the observation period compared to dienogest therapy. The use of combination therapy for adenomyosis improves the physical and psychological health components. Conclusions. Comprehensive therapy for adenomyosis normalizes the levels of tumor markers, immune and humoral status, stabilizes hematological parameters compared to dienogest therapy, and improves quality of life.
Full text 4,445 characters · extracted from oa-doi-fallback · 3 sections · click to expand

Abstract

Background: Adenomyosis is accompanied by impaired menstrual function, reproductive health, pain syndrome, anemia, and reduces the quality of life of women. Aim: to assess the impact of complex therapy for adenomyosis on immunological status, hormonal homeostasis, and quality of life in women of reproductive age.

Materials

and methods. The effect of hormone therapy was evaluated in 90 women with adenomyosis (main group), who were divided into two comparable groups depending on the treatment received. Women in group I (n=45) used complex therapy: gonadotropin-releasing hormone agonist, immunomodulator, vaginal suppositories with hyaluronic acid, rectal suppositories with streptokinase and streptodornase; group II (n=45) received dienogest once a day for 6 months. Health indicators were assessed 3, 6 and 12 months. Control group of 30 healthy women of reproductive age. Results. The effects of combination therapy and dienogest on the clinical course, menstrual blood loss volume, and indicators of immune and humoral homeostasis in women with adenomyosis were studied. The treatment led to a 3.7-fold decrease in the tumor marker CA 125, a 1.3-fold increase in hemoglobin levels, a 4.4-fold increase in ferritin, a 2.5-fold increase in serum iron, a 1.7-fold increase in the cytotoxic index of NK cells, a 2-fold decrease in FSH, a 1.5-fold decrease in LH, and a 1.9-fold decrease in estradiol during the observation period compared to dienogest therapy. The use of combination therapy for adenomyosis improves the physical and psychological health components. Conclusions. Comprehensive therapy for adenomyosis normalizes the levels of tumor markers, immune and humoral status, stabilizes hematological parameters compared to dienogest therapy, and improves quality of life.

References

Vovk-Shulha S.O., Khmil, S.V. Epidemiology and risk factors of uterine leiomyoma and genital endometriosis. Bulletin of social hygiene and health care organizations of Ukraine, 2024;1:81-88. [in Ukrainian]. DOI: https://doi.org/10.11603/1681-2786.2024.1.14629. Pados G., Gordts S., Sorrentino F., Nisolle M., Nappi L., Daniilidis A. Adenomyosis and infertility: a literature review. Medicina, 2023;359(9):1551. DOI: 10.3390/medicina59091551. Zhai J, Vannuccini S, Petraglia F, Giudice LC. Adenomyosis: mechanisms and pathogenesis. Semin Reprod Med 2020;38(2–03):129–143 DOI: 10.1055/s-0040-1716687. Semeniuk LM, Demyanenko LV, Chernukha LS, Kryzhanovska OI. Sexual dysfunction as an early marker of endometriosis. Clinical Endocrinology and Endocrine Surgery. 2020;2(70):86-91. [in Ukrainian]. DOI: https://doi.org/10.30841/2708-8731.7-8.2021.250830. Nodler JL, Harris HR, Chavarro JE, Frazier AL, Missmer SA. Dairy consumption during adolescence and endometriosis risk. Am J Obstet Gynecol. 2020;222(3): 257.e1-e16. DOI: 10.1016/j.ajog.2019.09.010. Smolarz B, Szyłło K, Romanowicz H. Endometriosis: Epidemiology, classification, pathogenesis, treatment and genetics (review of literature). International Journal of Molecular Sciences. 2021;22(19):10554. DOI: 10.3390/ijms221910554. Beniuk VO, Altibaeva DM, Goncharenko VM, Kurochka VV. The role of immune mechanisms in the development of benign uterine pathology. Health Women. 2016;(5):30-32. [in Ukrainian]. DOI: 10.15574/HW.2016.111.30. Scherbyna M, Chekhunova A. The state of the cytokine profile in patients with adenomyosis. Neonatol Surg Perinatal Med. 2022;12(43):43-49. DOI: 10.24061/2413-4260.XII.1.43.2022.8. Korzhevsky O.I., Yuryeva L.M. Etiopathogenesis of adenomyosis and modern approaches to its treatment. Medical sciences «Colloquium-journal» 2025;52(245):48-51. [in Ukrainian]. Available on: https://colloquium-journal.org/wp-content/uploads/2025/08/Colloquium-journal-2025-245-2.pdf#page=49. Boychuk AV. Endometriosis: Modern guidelines and practical experience of treatment. Obstetrics, Gynecology, Reproductive medicine. 2021;41(5):12-4. [in Ukrainian]. Available on: https://health-ua.com/akusherstvoginekologiya/zapalni-ta-disbioticni-zaxvoriuvannia/64525-endometroz-suchasn-gajdlajni-tapraktichnij-dosvd-lkuvannya. Ministry of Health of Ukraine. Unified clinical protocol of primary and specialized medical care “Tactics of management of patients with genital endometriosis”. 2016. Order No. 319; 2016 April 06. Available on: https://www.dec.gov.ua/mtd/genitalnyj-endometrioz/. This work is licensed under a Creative Commons Attribution 4.0 International License.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

adenomyosis

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (8)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK